




World Health
Organization

Mini-cPIE Clinic 1 
(COVID-19 Vaccination IAR)


**Global Overview and
Country Experience Sharing**

28 July 2021



Interpretation in French and Spanish is available by clicking **Interpretation** button


Click on “Interpretation” and choose the language that you would like to hear. To hear the interpreted language only, click “Mute Original Audio”





The PowerPoint, recordings, and all resources will be shared after the call.

Use the **Q&A** feature for questions throughout the call





Start poll

Overview

Overview of COVID-19 vaccination IAR (mini-cPIE)

Country experience sharing - The Kingdom of Bhutan

Country experience sharing - The Gambia

Country experience sharing - The Republic of Senegal

Q&A



- To create a **platform for countries to share their learnings and experiences** with peer countries on their review and adjustment to COVID-19 vaccine roll-out using the mini-cPIE tools.
- To cultivate a community of learning for COVID-19 vaccine roll-out and **directly connect countries with one another** to maximize on peer-learning.
- To provide opportunities for countries interested in reviewing their COVID-19 vaccine roll-out to **receive practical tips and technical support on how to conduct a mini-cPIE.**



What is an intra-action review (IAR)?



- A **country-led facilitated discussion** that allows national and subnational stakeholders of the COVID-19 response to:

- 1) reflect on the ongoing COVID-19 outbreak response at the country level to **identify current best practices, gaps and lessons learned**, and
- 2) propose **corrective measures** and actions to **improve and strengthen the continued COVID-19 response**.

- Additionally, IAR findings and recommendations may contribute to improved management of **concurrent emergencies**.



COVID-19 vaccination IAR (vaccination pillar)



1. Country-level coordination, planning and monitoring



2. Risk communication, community engagement and infodemic management



3. Surveillance, case investigation and contact tracing



4. Points of entry



5. National laboratory system



6. Infection prevention and control



7. Case management and knowledge sharing



8. Operational support and logistics in supply chain and workforce resilience



9. Strengthening essential health services




10. COVID-19 vaccination



11. Vulnerable and marginalized populations



12. National legislation and financing



13. Public health and social measures



14. Other possible topics and cross-cutting issues

COVID-19 vaccination IAR (Mini-cPIE)

“Classic” COVID-19 Vaccine Post-Introduction Evaluation (cPIE)

WHEN

2-6 months post-introduction (Early phase)

6-18 months post-introduction (Mid to long phase)

FORMAT

- **WHO COVID-19 Intra-Action Review (IAR)** methodology:
 - **Selected trigger questions** guide discussion.
 - Pre-review of key documents/indicators from **routine monitoring data**.
- Conducted online or face-to-face or a combination.

- Comprehensive evaluation including site visits.
- **7 questionnaires:** national, subnational, vaccination facility/site, health worker and other priority populations, immunization session observation, storage observation.

FREQUENCY

- **Optional but strongly recommended** to review COVID-19 vaccination implementation **at least once** in the early phase post-introduction.
- Countries may do **multiple reviews** focusing on different aspects of the roll-out and as vaccine products and target populations change.

- **Optional but strongly recommended** to conduct **at least once or more cPIE** in the mid to long phase of post-introduction.

OTHER KEY CHARACTERISTICS

- **Program areas align with NDVP and “classic” cPIE.**
- A minimum set of **key questions strongly recommended**, with **other questions optional**.

- Data and findings from COVID-19 vaccination IAR (mini-cPIE) can inform the cPIE.

Timeline of mini-cPIE and "classic" cPIE




EXAMPLE

EARLY PHASE

COVID-19 vaccination IAR (Mini-cPIE)
2-6 months post-introduction

MID TO LONG-TERM PHASE

"Classic" cPIE
6-18 months post-introduction



COVID-19 vaccination specific IAR (mini-cPIE) tools



COVID-19 vaccination IAR Trigger question database



COVID-19 vaccination IAR Note-taking template



COVID-19 vaccination IAR Final report template

PROGRAM EVALUATION AREA	SECTION
REGULATORY PREPAREDNESS	A
PLANNING, COORDINATION, & SERVICE	B
FUNDING	C
SUPPLY CHAIN & WASTE MANAGEMENT	D
HUMAN RESOURCE MANAGEMENT &	E
VACCINE ACCEPTANCE & DEMAND	F
VACCINE SAFETY	G
MONITORING & EVALUATION	H

Relevant documents to review	Relevance for this IAR
National Deployment and Vaccination Plan (NDVP) and other national vaccination planning and coordination documents	Please select relevancy
Training materials/reference documents used at COVID-19 vaccination training sessions	Please select relevancy
Media campaigns/social mobilization/education materials (e.g., brochures, posters, leaflets)	Please select relevancy
Risk Communication and Community Engagement (RCCE) Action Plan	Please select relevancy
COVID-19 vaccination report(s) at the national, regional, or global level since the start of implementation, including vaccine uptake, drop-out, and wastage (e.g. HMIS reports, immunization registry reports, e-IRF monthly reports)	Please select relevancy
COVID-19 vaccination recording and reporting tools (e.g. vaccination cards, tally sheets, registers, reporting forms)	Please select relevancy
COVID-19 vaccine AEFI guideline and reporting form(s)	Please select relevancy
COVID-19 vaccine AEFI reports since the start of implementation, by vaccine product	Please select relevancy
Listing of target population denominator estimates and data sources (including years)	Please select relevancy
Supportive supervision checklist for COVID-19 vaccination, aggregated results	Please select relevancy
Health Service Capacity Assessment, COVID-19 vaccine readiness module 8, results	Please select relevancy
Survey or qualitative results collected using Behavioral and Social Driver (BeSD) tools ¹⁰	Please select relevancy
Vaccine effectiveness and/or impact protocols and results (as available)	Please select relevancy

Possible indicators ^[2,3]	Relevance for this IAR
For each COVID-19 vaccine product in use in the country:	Please select relevancy
Date of first introduction, number of vaccine doses received, number of doses administered	Please select relevancy
Weekly/Monthly % COVID-19 vaccine uptake ¹⁰ (for all vaccinations and disaggregated by geographic area, by subgroups, by delivery strategy and by vaccine product)	Please select relevancy
Number of persons vaccinated with at least one dose of COVID-19 vaccine (for all vaccinations and disaggregated by geographic area, by subgroups, by delivery strategy, and by vaccine product)	Please select relevancy
Number of persons fully vaccinated, per manufacturer recommendation for all vaccinations and disaggregated by geographic area, by subgroups, by delivery strategy, and by vaccine product	Please select relevancy
(For 2 dose vaccines) Proportion drop-out from 1st dose to 2nd dose (Calculated as: (COV1-COV2)/COV1) ¹⁰	Please select relevancy
Average estimated open and closed vial vaccine wastage by vaccination site and product	Please select relevancy
Existence of a functioning bulletin or dashboard for vaccination uptake monitoring at the national level	Please select relevancy
% of all vaccine doses distributed/administered by the private sector	Please select relevancy
Number of individuals trained for COVID-19 vaccine delivery/administration, total and by job category	Please select relevancy
% of prioritized health workers who were fully vaccinated with COVID-19 vaccine, per manufacturer recommendation	Please select relevancy

Country COVID-19 Intra-action review (IAR)

Note-taking template
March 2021

Note-taking template for Country COVID-19 Intra-Action Review (IAR)
Pillar 10: COVID-19 Vaccination

[COUNTRY]
Date(s) of Intra-Action Review: DDMMYYYY

Instructions:

- This template will be used by the notetaker during the IAR.
- The table below should be duplicated, so one table can be completed for each of the program evaluation areas of Pillar 10: COVID-19 vaccination.
- In the table, the sections on "Best practices" and on "Challenges" should be completed during the session "STEP 1". The section on "Recommended actions" should be completed during the session "STEP 2".

PILLAR 10: COVID-19 Vaccination	Document Existing Systems
1. Programs for vaccination of COVID-19 risk groups	Note if new programme or adaptations to existing systems were required
2. National Immunization Technical Advisory Group (NITAG)	
3. Adverse events following immunization (AEFI) causality assessment committee	

PILLAR 10: COVID-19 Vaccination	Section A: Regulatory Preparedness	ENABLING FACTORS
BEST PRACTICES	1. Best practice 1:	Impact 1: Enabling factor 1
		Impact 2: Enabling factor 2
	2. Best practice 2:	Impact 1: Enabling factor 1
CHALLENGES	1. Challenge 1:	Impact 1: Limiting factor 1
		Impact 2: Limiting factor 2
	2. Challenge 2:	Impact 1: Limiting factor 1

Country COVID-19 Intra-action Review (IAR) Report

Country COVID-19 Intra-action review (IAR):
Final report template
March 2021

COUNTRY COVID-19 INTRA-ACTION REVIEW (IAR)
COVID-19 VACCINATION
REPORT

[COUNTRY]
[LOCATION, DDMMYYYY]

- This template should be used by the designated report writer to highlight the key findings and recommendations arising from the review, instead of a duplication of the content of the note-taking template.
- This report should preferably be kept as short and concise as possible. Additional background, contextual information, as well as tables from the note-taking templates, should be moved to the annexes.
- This report should be shared with participants for their comments to ensure information are accurately captured before validation by senior management.

Countries are encouraged to share their IAR findings through their final report by using this template or part of their IAR findings through their success stories (see tool n°10). We encourage countries to share their IAR final report or success stories with other countries, WHO and partners to enable peer-to-peer learning of best practices or new capacities implemented in the country, via their own ministry website or others such as WHO's COVID-19 Partners Platform, WHO's Strategic Partnership Portal, etc.

Do not hesitate to contact your WHO country office or regional office for technical assistance.

Page 1 of 12

Global mini-cPIE implementation status

As of 27 July 2021



Conducted a mini-cPIE

AFR AMR EMR EUR SEAR WPR

Botswana
Ethiopia
Gambia
Ghana
Senegal
Uganda

Somalia

Bhutan



Planning to conduct a mini-cPIE

AFR AMR EMR EUR SEAR WPR

DRC
Guinea-Bissau
Liberia
Madagascar
Namibia
Niger
Sierra Leone
South Sudan
Togo
Zambia

Lebanon
Morocco
Syrian Arab Republic

Indicated interest in conducting a mini-cPIE

AFR AMR EMR EUR SEAR WPR

Algeria
Burkina Faso
Cameroon
Lesotho
Mali
Nigeria
São Tomé and Príncipe


Barbados
Bolivia
El Salvador
Haiti
Trinidad and Tobago

Pakistan
Tunisia

Albania
Moldova

India
Indonesia
Sri Lanka

Lao PDR
Mongolia
Vietnam





COVID-19
INTRA-ACTION REVIEW



COVID-19
VACCINATION PILLAR

Mini-cPIE Clinic 1 (COVID-19 Vaccination Intra-Action Review)

EXPERIENCE SHARING FROM COUNTRIES

EXPERIENCE SHARING FROM **BHUTAN**

Mini-cPIE (COVID-19 Vaccination Intra-Action Review)




Dr SONAM WANGCHUK
NITAG members



Mini-cPIE (COVID-19 Vaccination Intra-Action Review)

Preparation Phase | Implementation Phase





Mini-cPIE (COVID-19 Vaccination Intra-Action Review)

Date of the review : 5-6 May 2021


Format : Conducted onsite

Partner involvement: Executives from MoH involved in vaccination campaign from various Departments, Members of the NITAG, Members of the TAG for COVID-19, Data Managers, District Health Officers, UNICEF, UNDP and WHO

Finance : WHO



Areas of review :

1. Planning, Coordination & Funding
2. Supply Chain & Waste Management
3. Vaccine Safety & Training
4. Media and Risk Communication
5. Data recoding reporting




Key Milestones of the COVID-19 Vaccine Roll-Out

- Bhutan received 550,000 doses of Covishield as donation from India in two tranches by 22 March, 2021.
- 1st dose Nationwide vaccination campaign was launched on 27 March for 10 days.
- Prime Minister and the Member of Parliament received the first dose that increased the confidence among the people.
- 1st dose Nationwide vaccination campaign coverage was around 95%.
- Bhutan received 500,000 Moderna and 125,000 doses of Astrazeneca as donation from USA and Denmark. 5850 doses of Pfizer from COVAX.
- Prime Minister and voluntary participants participated in heterologous test dose.
- 2nd dose nationwide campaign was launched on 20th July for 7 days (20-26th July)



Key Milestones of the COVID-19 Vaccine Roll-Out



During the second dose vaccine campaign, Bhutan had:

- 1217 VACCINATION POSTS
- 4868 HEALTH WORKERS
- 2161 DESUUNG VOLUNTEERS

SECOND DOSE STATS.



GOOD PRACTICES & CHALLENGES

GOOD PRACTICES

Experience of nation-wide influenza vaccination roll-out in 2020 season

Zoning system and village clustering identified for testing during lockdowns as been useful for vaccination roll-out

Daily debriefing was conducted during campaign chair by Health Minister with MoH Executives who were deployed in the field to review progress and logistic challenges

Field experience was shared by District Health Office. One presenter was identified and invited from the three region to share their good practices and challenges to improve 2nd nation-wide vaccination campaign

CHALLENGES

Training of healthcare workers on vaccination roll-out

Inadequate training on use of Bhutan Vaccination system data inconsistency

Participants from high risk areas could not be participated in person for review meeting because of mandatory quarantine require to travel to low risk area



IMPACT ON THE COVID-19 VACCINE ROLL-OUT

CHANGES TRIGGERED BY THE MINI-CPIE

IMPACT ON COVID-19 VACCINE ROLL-OUT

- 1. Strengthening of the Bhutan Vaccine system by adding some variables and re-training health workers involved in vaccination campaign**
- 2. Allocate budget for mobile voucher, travel allowance and refreshments and set clear financial guidance on COVID-19 vaccination campaign**
- 3. Decentralization of vaccine supply management to health centers in bigger urban areas**

Smooth roll out of vaccination registration and reporting system. Inventory function for vaccine was made live and accessible for supply management

Budget allocated and clear financial guidelines prevented confusion and delay in settling expenditure

Ensured a more manageable supply and cold chain management system preventing delay in supply and wastage



IMPROVING THE COVID-19 VACCINE ROLL-OUT

IMPROVING THE ONGOING COVID-19 VACCINE ROLL-OUT

1. What is the number one thing you would do differently or change about the COVID-19 vaccination programme going forward?

- Strategize the vaccination program by risk areas and priority groups based on supply of vaccine

2. What best practices can be identified from the country's implementation of COVID-19 immunization, and how can these be further strengthened and instituted?

- The utilization of the digital solution i.e the Bhutan Vaccine System (BVS) for registration of eligible population, pre-screening questionnaires, record immunization and report AEFI online in real-time.
- Options for additional data field like vaccine inventory.
- Need to ensure more disaggregation of data for meaningful analysis.
- Need in built system to prevent duplication
- Institute regional AEFI committee and build their capacity



IMPROVING THE COVID-19 VACCINE ROLL-OUT

IMPROVING THE ONGOING COVID-19 VACCINE ROLL-OUT

3. What is the most important piece of advice you would give another country just starting their program?

- **Adopt digital solution to get real time data to help monitor and strengthen roll out of vaccination program.**
- **Media advocacy and risk communication through politician, community leader, religious leaders and other influencer like actors and public known figure**
- **Political commitment is critical for successful vaccination roll-out**



CERTIFICATE OF ACHIEVEMENT

NOTE:

WHO will send this to countries after you share your mini-cPIE findings via final report, executive summary or exemplar stories!



Questions welcome!

For more information on any of the
material presented, please contact:

Dr.Sonam Wangchuk
swangchuk@health.gov.bt



EXPERIENCE SHARING FROM **THE GAMBIA**

Mini-cPIE (COVID-19 Vaccination Intra-Action Review)



**SIDAT FOFANA
EPI TEAM LEAD
MINISTRY OF HEALTH
THE GAMBIA**



Mini-cPIE (COVID-19 Vaccination Intra-Action Review)

DESCRIPTION OF THE ACTIVITY *(what was done: geographical scope, programme evaluation areas reviewed, etc.)*

- **Vaccination IAR in The Gambia**
- **Areas reviewed:**
 - Regulatory preparedness,
 - Planning, Coordination and Service Delivery
 - Funding
 - Supply Chain and Waste Management
 - Human Resource Management and Training
 - Vaccine Acceptance & Demand/Risk Communication and Community Engagement
 - Vaccine Safety
 - Monitoring and Evaluation

ADDITIONAL INFORMATION

- **Review period: 5th March 2021 – 28th June 2021**
- **Date of review: 28th – 29th June, 2021**
- **Format: online & onsite for 48 participants from MoH, UN organizations, INGOs**
- **Partner involvement: Technical and financial**
- **Vaccine product reviewed: AstraZeneca**



Key Milestones of the COVID-19 Vaccine Roll-Out

Activity	Dates
NDVP developed & approved	Feb 2021
Micro plan developed (national & regional)	Mar 2021
Training of HCWs	20-25 May 2021
Trainings of canvassers	5/3/2021
Vaccination roll-out	
National launching at State House	10/3/2021
Launching at regional levels	
Training of national AEFI committee	18-21 May 2021
Training of regional AEFI committee	21-22 May 2021
Regional Mobilization of TACS/District Chiefs/Alikalos	
Radio and TV spots	
TV and Radio panel discussion	
COVID-19 vaccination caravan	18-4 May 2021

Activity	Dates
Orientation of Faith base organisation - national	April
Orientation of Faith base organisation - regional	April- May
Sensitization of organised groups (mothers club, women groups, VSGs, Youth and TCs)Region	April - May
Production of communication support materials	Apr- May
Readiness assessment for the COVID-19 vaccine delivery	-
Review, update and validation of data collection tools	Feb
Training of incinerator attendants on waste management	
Ended 1 st consignment of AZ vaccines	28/6/2021
Vaccination Intra-Action Review	28-29/6/2021



GOOD PRACTICES & CHALLENGES

GOOD PRACTICES

- Government/donor funding support for the COVID-19 vaccine
- National, regional and institutional launching of vaccination
- Adequate cold chain capacity at all levels to store COVID-19 vaccines
- AEFI committee formed and trained at central and regional levels
- Existence of trained human resources to manage vaccines and supplies
- Available NDVP with prioritized groups from vaccination

CHALLENGES

- Doubtful vaccine quality and effectiveness due to the indemnity clause
- Vaccine hesitancy
- Inadequate financial commitment for vaccination operational cost
- Non-implementation of the NDVP
- Inadequate stock of electronic reporting tools
- Limited coordination between National Communication Committee and AEFI committee



IMPACT ON THE COVID-19 VACCINE ROLL-OUT

CHANGES TRIGGERED BY THE MINI-CPIE

IMPACT ON COVID-19 VACCINE ROLL-OUT

- 1. - MoH released funds for vaccination operations costs**
- 2. - Engagement of private hospitals as static posts for COVID-19 vaccination**
- 3. - Improved collaboration between EPI team and logistics sub-committee**
- 4. - Robust engagement of all stakeholders to address vaccine hesitancy**

- Ease of implementation of NDVP planned activities**
- Improved coverage of communities as some people do not visit public hospital for health needs.**
- Better logistics support for vaccination activities.**
- Improved turn-out for vaccination/improved coverage for the prioritized groups**



IMPROVING THE COVID-19 VACCINE ROLL-OUT

IMPROVING THE ONGOING COVID-19 VACCINE ROLL-OUT

1. What is the number one thing you would do differently or change about the COVID-19 vaccination programme going forward?

- The delayed release of funds to support operational costs for vaccination
- Non-implementation of NDVP planned activities

2. What best practices can be identified from the country's implementation of COVID-19 immunization, and how can these be further strengthened and instituted?

- GoTG/Partners' funding. Emergency funds should be set aside and processes for accessing it be simplified
- National, regional and institutional launching of vaccine

3. What is the most important piece of advice you would give another country just starting their program?


- Simplify funds' release and implement the NDVP planned activities



CERTIFICATE OF ACHIEVEMENT

NOTE:

WHO will send this to countries after you share your mini-cPIE findings via final report, executive summary or exemplar stories!



Questions welcome!

For more information on any of the
material presented, please contact:

Dr Sidat Fofana
sidatfofana@yahoo.co.uk



EXPERIENCE SHARING FROM **COUNTRY NAME : SENEGAL**

Mini-cPIE (COVID-19 Vaccination Intra-Action Review)



PRESENTATOR'S NAME : Dr Boly DIOP

TITLE : Chef DSRV

ORGANISATION : MSAS

COUNTRY: Senegal



ADDITIONAL INFORMATION

- **Période couverte par la RIA : 01/12/2020 - 30/06/2021**
- **Date de la RIA : 06-09/07/2021**
- **Format : mixt online and onsite**
 - 45 participants
 - Directions et Services du niveau central, Régions Médicales, Districts sanitaires et Acteurs communautaires
 - Multisectorielle : Santé, Enseignement Supérieur, Collectivités territoriales
- **Partner involvement : OMS, UNICEF, CDC, USAID/MTAPS**
- **Vaccine product reviewed : Sinopharm, Astra Zeneca**



PHASE PREPARATOIRE

- **Option d'une RIA nationale**
- **Recueil de la documentation appropriée des activités de déploiement des vaccins et des données de la planification à la mise en œuvre ;**
- **Les données du programme et les rapports sur le terrain, compilés et analysés ;**
- **L'agenda consolidé a été envoyé aux différentes parties prenantes ;**
- **Le choix des coordonnateurs de sessions et des rapporteurs a été fait lors de la journée préparatoire ;**



METHODOLOGIE

- **Les présentations en plénière ont été faites et les discussions ont eu lieu sur les productions ;**
- **Les groupes thématiques ont été mis en place (composés de personnes ressources pertinentes de tous les niveaux et de diverses agences) pour une analyse et des discussions intensives autour des questions de déclenchement pour chaque domaine thématique**
- **Les principaux points de discussion ont été documentés et des points d'action générés**
- **Les groupes thématiques ont présenté leurs conclusions et recommandations en plénière pour une discussion plus large, un enrichissement et une validation des points d'action**
- **Les résultats consolidés, les recommandations, les points d'action et les leçons apprises ont été documentés et partagés avec les parties prenantes concernées.**



DOMAINES DE LA RIA

- **Préparation générale et coordination du déploiement des vaccins**
 - L'approbation réglementaire
 - Préparation opérationnelle
 - Mobilisation et allocation des ressources
 - Formation des agents de santé et des volontaires
- **Logistique**
 - Vaccins et équipement de la chaîne du froid
 - Outils et autres intrants
 - Moyens de transport
- **Qualité de la prestation de services**
 - Mesures de prévention et de contrôle des infections
 - Suivi et supervision
 - Données et documentation (tenue de registres et analyse des données)




DOMAINES DE LA RIA

- **Communication**
 - **Génération de la demande et engagement communautaire**
 - **Écoute sociale**
 - **Hésitation**
- **Sécurité de la vaccination**
 - **Surveillance des MAPI et évaluation de la causalité**
 - **Gestion des MAPI**



Key Milestones of the COVID-19 Vaccine Roll-Out





GOOD PRACTICES & CHALLENGES

GOOD PRACTICES

- 1. Coordination et planification inclusive en utilisant les organes classiques (CCIA et sous-comités, CCVS)**
- 2. Le Suivi en temps réel des stocks dans les régions de Dakar et Diourbel à travers logistimo dans un projet pilote**
- 3. Diffusion de capsules audio et vidéos sur les réseaux sociaux (WhatsApp)**

CHALLENGES

- 1. Non-respect strict du ciblage lors de la première phase de vaccination**
- 2. Thésaurisation des vaccins au niveau de certaines régions**
- 3. Absence de procédures pour la prise en charge gratuite des MAPI graves**



GOOD PRACTICES & CHALLENGES

GOOD PRACTICES

- 4. Priorité accordée aux personnes vulnérables pour la première phase de la vaccination**
- 5. Le monitoring de la date de péremption par lot pour le redéploiement vers les régions à forte consommation**
- 6. Investigation de tous les cas de MAPI graves**

CHALLENGES

- 4. Insuffisance dans l'animation du pilier vaccination dans le SGI**
- 5. Insuffisance de rapportage et d'archivage des données logistiques**
- 6. Insuffisance de communication sur les MAPI (CIP et communication de masse)**



IMPACT ON THE COVID-19 VACCINE ROLL-OUT

CHANGES TRIGGERED BY THE MINI-CPIE

IMPACT ON COVID-19 VACCINE ROLL-OUT

1. Tenue de reunion du comité de pharmacovigilance pour l'imputabilité de tous les cas de MAPI

Confiance de la population sur la vaccination

2. Coordination et planification inclusive en utilisant les organes classiques (CCIA et sous-comités, CCVS)

Maitrise du processus d'acquisition des vaccins

3. Utilisation du même circuit que pour les autres vaccins de routine (COVAX)....

Disponibilité des vaccins dans les structures sanitaires

4. Disponibilité d'un système de gestion sanitaire digitalisé COVID-19

Meilleur suivi des performances de la vaccination en temps réel



IMPROVING THE COVID-19 VACCINE ROLL-OUT

IMPROVING THE ONGOING COVID-19 VACCINE ROLL-OUT

1. What is the number one thing you would do differently or change about the COVID-19 vaccination programme going forward?

Mettre en place des PON pour la gestion des MAPI graves (surveillance active, PEC gratuite et communication)

2. What best practices can be identified from the country's implementation of COVID-19 immunization, and how can these be further strengthened and instituted?

Redéploiement inter et intra régional pris en charge par les régions médicales
Ce qui a permis d'utiliser les vaccins dont la date péremption était proche

3. What is the most important piece of advice you would give another country just starting their program?


Recensement exhaustif de la cible prioritaire au niveau de certains PPS



CERTIFICATE OF ACHIEVEMENT

NOTE:

WHO will send this to countries after you share your mini-cPIE findings via final report, executive summary or exemplar stories!



Questions welcome!

For more information on any of the
material presented, please contact:

Dr Boly DIOP
diopboly@yahoo.fr





Feedback or Questions





End poll

Available resources



IAR Guidance and Tools




https://www.who.int/publications/i/item/WHO-2019-nCoV-Country_IAR-2020.1

IAR guidance and tools (version 1.0) are available in all six UN languages (Arabic, Chinese, English, French, Russian, Spanish) + Portuguese

IAR addendum and updated and additional tools (version 2.0) are currently in English but will be available in all six UN languages and Portuguese soon!

mini-cPIE (COVID-19 vaccination IAR) specific tools



<https://www.who.int/tools/covid-19-vaccine-introduction-toolkit#Evaluation%20of%20COVID-19%20vaccine%20introduction>

OpenWHO IAR online course



<https://openwho.org/courses/covid-19-intra-action-review-en/>

Available in Arabic, English, French, Russian, Spanish and Portuguese!



- Full report
- Executive summary, including overall best practices and challenges
- Exemplar stories (aspects of **specific program areas** to highlight)
- **Present in the next mini-cPIE clinic!**

NOTE: Country IAR core team will receive a **Certificate of Achievement upon sharing COVID-19 vaccination IAR results for peer learning.**





To watch the training webinar
“**Mini-cPIE (COVID-19 vaccination IAR) –
What is it and how to conduct one?**”,
please go to [link](#) or download the pdf slides [here](#).

For more information and technical support on any
of the material presented, please contact:


Jenny Walldorf (walldorfj@who.int)
Landry Ndriko Mayigane (mayiganel@who.int)
Cindy Chiu de Vázquez (chiuc@who.int)



https://www.who.int/publications/i/item/WHO-2019-nCoV-Country_IAR-2020.1

<https://www.who.int/tools/covid-19-vaccine-introduction-toolkit#Evaluation%20of%20COVID-19%20vaccine%20introduction>

Short video on IAR methodology



COVID-19 best practices at country level through Intra-Action Reviews (IAR)

[3:47]

English: <https://youtu.be/n8PUfV6WbYc>

French: <https://youtu.be/VITmjbrTp-k>

Arabic: <https://youtu.be/z6ALhmSqPNw>

Chinese: <https://youtu.be/H5gaagtI6JI>

Russian: <https://youtu.be/uyRkpdhoXSU>

Spanish: <https://youtu.be/pxrudMAM2gg>